Key terms
About MRNS
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MRNS news
Today
12:26am ET
Maintaining Buy Rating on Marinus: A Balanced View on Future Prospects Despite RSE Setback
Apr 16
7:35am ET
Oppenheimer Sticks to Its Hold Rating for Marinus (MRNS)
Apr 16
4:56am ET
Marinus Pharmaceuticals downgraded to Neutral from Outperform at Baird
Apr 16
4:46am ET
Maintaining Hold on Marinus Amid Clinical Setbacks and Uncertain Financial Outlook
Apr 15
1:25pm ET
Maintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial Health
Apr 15
1:05pm ET
Marinus Pharmaceuticals: A Strong Buy Despite RAISE Trial Setback, with Promising Growth Potential in DEE Market
Apr 15
12:55pm ET
Marinus Pharmaceuticals downgraded to Sector Perform at RBC Capital
Apr 15
11:45am ET
Maintaining Buy Rating on Marinus Stock: Analyzing Ganaxolone’s Potential Beyond Interim RAISE Study Results
Apr 15
7:14am ET
Marinus expects Phase 3 Trust TSC trial of ZTALMY in mid-May 2024
Apr 15
7:12am ET
Marinus Pharmaceuticals sees Q1 revenue $7.4M-$7.6M, consensus $9.08M
Apr 15
7:08am ET
Marinus trial did not meet stopping criteria at the interim analysis
Apr 08
10:20pm ET
Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), uniQure (QURE) and eFFECTOR Therapeutics (EFTR)
Apr 08
6:30am ET
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Marinus (MRNS) and Halozyme (HALO)
Mar 28
7:50am ET
Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)
Mar 27
8:50am ET
Marinus Comments on patent challenge by Ovid Therapeutics
Mar 26
8:10am ET
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)
Mar 26
7:06am ET
Marinus (MRNS) Gets a Buy from Cantor Fitzgerald
Mar 26
6:16am ET
Buy Rating Affirmed for Marinus Pharmaceuticals with Promising Outlook for Ganaxolone in RSE Treatment
Mar 11
5:55pm ET
Marinus Pharmaceuticals management to meet with Jefferies
Mar 11
10:28am ET
Marinus Pharmaceuticals management to meet with Jefferies
Mar 07
12:45pm ET
Marinus Pharmaceuticals’ ganaxolone approved by MHRA
Mar 07
7:38am ET
Marinus (MRNS) Receives a Hold from Oppenheimer
Mar 06
11:57pm ET
Buy Rating Affirmed on Marinus Pharmaceuticals Amid Strong Clinical Pipeline and Positive Trial Milestones
Mar 06
11:16pm ET
Marinus Pharmaceuticals Earns Buy Rating from Analyst on Strong Sales and Promising Pipeline
Mar 06
8:06am ET
Marinus (MRNS) Receives a Rating Update from a Top Analyst
Mar 06
7:35am ET
Buy Rating Affirmed: Marinus’s Promising Clinical Trials and Revenue Projections
Mar 06
7:20am ET
Analysts Offer Insights on Healthcare Companies: SOPHiA GENETICS (SOPH), Green Thumb Industries (OtherGTBIF) and Marinus (MRNS)
Mar 06
6:46am ET
Michael Higgins Endorses Marinus with a Buy Rating Amidst Promising Trials and Strong Financial Outlook
Mar 06
12:30am ET
Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Marinus (MRNS) and Gritstone Oncology (GRTS)
Mar 05
11:55pm ET
Optimistic Buy Rating for Marinus Pharmaceuticals Based on Promising Clinical Trials and NDA Potential
Mar 05
4:06pm ET
Marinus Pharmaceuticals sees FY24 U.S. ZTALMY revenue $32M-$34M
MRNS Financials
Key terms
Ad Feedback
MRNS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MRNS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
